Beclomethasone Dipropionate Monohydrate

Sold as Beconase Aq, Vancenase Aq. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 3 applications for Beclomethasone Dipropionate Monohydrate (sold as Beconase Aq, Vancenase Aq), first approved Jul 27, 1987, with 0 new uses approved and 0 published complete response letters.

First approved: Jul 27, 1987
Applications: 3
New uses approved: 0
Complete response letters: 0

Orphan Designations (FDA)

One designation, 0 approved for the designated use; see all orphan designations

For oral administration in the treatment of intestinal graft-versus-host disease.Soligenix, Inc. · designated Mar 27, 1998

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jul 27, 1987	Beconase AqNDA 19389 · New dosage form	Glaxosmithkline	22	Discontinued
Dec 23, 1987	Vancenase AqNDA 19589 · New formulation or manufacturer	Schering	5	Discontinued
Jun 26, 1996	Vancenase AqNDA 20469 · New dosage form	Schering	6	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA